Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Oligonucleotide Synthesis Market
The oligonucleotide synthesis market is projected to expand significantly from 2025 to 2035, driven by advancements in genomics, synthetic biology, and personalized medicine. The market encompasses oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment, serving therapeutic, research, and diagnostic applications across hospitals, pharmaceutical companies, diagnostic laboratories, CROs/CMOs, and academic research institutes. Growth is fueled by increasing demand for nucleic acid-based therapeutics, gene editing technologies, and precision medicine, with key players investing in innovation to meet evolving industry needs.
Market size
Growth trajectory through 2035
Oligonucleotide Synthesis Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Advancements in enzymatic synthesis
- Recent breakthroughs in enzymatic oligonucleotide synthesis are reducing costs and improving scalability, offering an alternative to traditional chemical synthesis methods.
-
Development 02 Expansion of mRNA-based therapeutics
- The success of mRNA vaccines, particularly during the COVID-19 pandemic, has accelerated investments in mRNA-based therapies, driving demand for high-quality synthesized oligonucleotides.
-
Development 03 Partnerships and collaborations
- Key players are forming strategic alliances to enhance synthesis capabilities, such as Twist Bioscience's collaborations with pharmaceutical companies for custom oligonucleotide production.
-
Development 04 Regulatory approvals
- Increasing regulatory approvals for oligonucleotide-based drugs, such as antisense therapies for rare diseases, are validating the market and encouraging further investment.
Emerging opportunities added
- Emerging markets in Asia-Pacific Rapidly growing biotechnology sectors in China, Japan, and India present untapped opportunities for oligonucleotide synthesis providers, supported by increasing government investments and collaborations.
- Expansion of mRNA-based therapeutics The success of mRNA vaccines and therapies has opened new avenues for oligonucleotide synthesis, particularly for vaccine development and infectious disease treatments.
- Integration with AI and automation Adoption of artificial intelligence and robotic synthesis platforms can enhance efficiency, reduce costs, and improve scalability, making oligonucleotide synthesis more accessible.
- Collaborations with CROs/CMOs Partnerships between oligonucleotide synthesis providers and contract research organizations (CROs) or contract manufacturing organizations (CMOs) can streamline drug development processes and expand market reach.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.61 Bn
- CAGR
- 14.10%
- Expansion
- 3.7×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- genetic testing.CROs
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High production costs
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Advancements in enzymatic synthesis: Recent breakthroughs in enzymatic oligonucleotide synthesis are reducing costs and improving scalability, offering an alternative to traditional chemical synthesis methods
+5 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Oligonucleotide Synthesis Market today ($10.61 Bn base), and how fast will it grow at 14.1% CAGR through 2035?
- Which of siRNA, aptamers, diagnostics and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across genetic disorders, viral infections.Research Applications: Supports academic, industrial research in genomics applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Amgen Inc, Gilead Sciences, Regeneron Pharmaceuticals and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Advancements in gene editing technologies) and top restraints (led by High production costs), with quantified CAGR impact?
- What regulatory shifts and 6 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Advancements in gene editing technologies Innovations such as CRISPR-Cas9 and other gene-editing tools are accelerating the development of nucleic acid-based therapeutics, driving demand for high-quality synthesized oligonucleotides.
- Rise of personalized medicine The shift toward tailored therapies, particularly in oncology and rare diseases, is increasing the need for custom oligonucleotide synthesis to support individualized treatment strategies.
- Expansion of synthetic biology Synthetic biology applications, including engineered organisms and metabolic pathways, rely on synthetic oligonucleotides for gene synthesis and modification, fueling market growth.
- Increased R&D investment Pharmaceutical and biotechnology companies are allocating greater resources to nucleic acid research, including antisense oligonucleotides, siRNA, and mRNA-based therapies, which require robust synthesis capabilities.
- Regulatory support and clinical validation Growing clinical evidence for oligonucleotide-based drugs and regulatory approvals are enhancing market confidence and adoption.
Restraints
Holding it back
- High production costs The synthesis of high-purity oligonucleotides remains capital-intensive, particularly for long or complex sequences, limiting accessibility for smaller firms and research institutions.
- Stringent regulatory requirements Compliance with Good Manufacturing Practices (GMP) and other regulatory standards increases operational complexity and costs, slowing market entry for new players.
- Supply chain vulnerabilities Dependence on specialized raw materials, such as phosphoramidites and solid supports, exposes the market to supply chain disruptions, impacting production timelines.
- Technical challenges in synthesis Limitations in achieving high yields for long oligonucleotides and maintaining sequence fidelity pose ongoing challenges, particularly for therapeutic applications.
- Ethical and safety concerns Public and regulatory scrutiny around gene editing and synthetic biology may temper market growth in certain regions or applications.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Advancements in gene editing technologies | +6.3% | Global | 2025–2035 |
| Rise of personalized medicine | +3.9% | Global | 2025–2035 |
| Expansion of synthetic biology | +3.1% | Global | 2025–2035 |
| Increased R&D investment | +2.1% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High production costs | −2.5% | Global | 2025–2029 |
| Stringent regulatory requirements | −1.7% | Global | 2025–2029 |
| Supply chain vulnerabilities | −1.3% | Global | 2025–2029 |
4 Oligonucleotid 3 Synthesized Ol 2 Reagents 1 Equipment The oligonucleotide synthesis market is segmented by product, application, end user, and region:
Revenue share by type · 2025 base year
% OF $10.61 BN OLIGONUCLEOTIDE SYNTHESIS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $10.61 Bn Oligonucleotide Synthesis Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
siRNA
-
aptamers
-
diagnostics
-
therapeutic development.Reagents: Essential chemicals
-
enzymes required for oligonucleotide synthesis
-
such as phosphoramidites
-
solid supports
-
activators.Equipment: Automated synthesizers
By application
-
genetic disorders
-
viral infections.Research Applications: Supports academic
-
industrial research in genomics
-
synthetic biology
-
including PCR-based tests
-
genetic screening tools
By end-user industry
-
genetic testing.CROs
-
synthetic biology
-
related fields
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.61 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~46.5% in 2025. The largest market, driven by a robust biotechnology sector, high R&D investments, and strong regulatory frameworks. The U.S. dominates the region, supported by the presence of major pharmaceutical a…
Per-region detail
-
North America
The largest market, driven by a robust biotechnology sector, high R&D investments, and strong regulatory frameworks. The U.S. dominates the region, supported by the presence of major pharmaceutical and biotechnology companies
-
Europe
A significant market, characterized by strong academic research institutions, government funding for life sciences, and a growing focus on personalized medicine. Countries such as Germany, the UK, and France are key contributors
-
Asia-Pacific
The fastest-growing region, fueled by increasing biotechnology investments, government initiatives, and a rising demand for nucleic acid-based therapeutics. China and Japan are leading contributors, with India emerging as a significant player
-
Latin America
A developing market with growing investments in healthcare and biotechnology. Brazil and Mexico are key markets, supported by increasing collaborations with global pharmaceutical companies
-
Middle East & Africa
A smaller but expanding market, driven by investments in healthcare infrastructure and partnerships with international biotechnology firms. The UAE and Saudi Arabia are notable contributors
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The oligonucleotide synthesis market is highly competitive, with a mix of established players and emerging innovators. Key companies are investing in R&D, strategic partnerships, and acquisitions to strengthen their market positions. The competitive landscape is shaped by the need for high-quality synthesis capabilities, regulatory compliance, and cost efficiency. Major players include:
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Amgen Inc
Rank 01Share est. ~16%Revenue $28B FYHQ US · Thousand Oaks -
Gilead Sciences
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Regeneron Pharmaceuticals
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Vertex Pharmaceuticals
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Biogen Inc
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Moderna Inc
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
BioNTech SE
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Alnylam Pharmaceuticals
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the expected CAGR in terms of revenue for the global oligonucleotide synthesis market over the forecast period (2020–2030)?
The global oligonucleotide synthesis market revenue is projected to expand at a CAGR of 13.1% during the forecast period. -
• What was the global oligonucleotide synthesis market valued at in 2023?
The global oligonucleotide synthesis market was valued at USD 3.18Billion in 2023. -
• Who are the key players in the oligonucleotide synthesis market?
The oligonucleotide synthesis market key players include Thermo Fisher Scientific, Merck KGaA, LGC Limited, Maravai Life Sciences, Alnylam Pharmaceuticals, Inc., Biogen Inc., Danaher Corporation, Eurofins Scientific, Ionis Pharmaceuticals, Inc., Kaneka Corporation. -
• What are the factors driving the oligonucleotide synthesis market?
Over the past few years, the market has seen a growth in demand for high quality synthesized oligonucleotides due to research institutes and diagnostic centers turning their attention to genomics and genetics. Antisense oligonucleotides were used as part of a novel therapy strategy developed by rosalind franklin university of medicine and science researchers to treat the neurological disease Batten disease, which is lethal in children, these elements are anticipated to fuel the growth of the worldwide oligonucleotide synthesis market. -
• What are the different segments of the global oligonucleotide synthesis market?
The global oligonucleotide synthesis market is divided into product, application, end user, and region. -
• Which region will lead the global oligonucleotide synthesis market?
The oligonucleotide synthesis market's largest regional section is North America, which consists of the US and Canada. The market for oligonucleotide synthesis was dominated by the North American region in 2022.
The Oligonucleotide Synthesis Market is projected to reach $39.68 Bn by 2035, up from $10.61 Bn in 2025 — a 14.10% CAGR equating to roughly 3.7× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.